Cedars-Sinai Cancer | Strategic Alliance Partners

Cedars-Sinai Cancer in Los Angeles serves one of the most diverse regions globally. Ranked No. 7 for cancer by U.S. News & World Report 2020-2021, the center’s clinicians are committed to providing compassionate, state-of-the-art care, while its scientists are carrying out the latest translational research and groundbreaking advances. The cancer enterprise includes the Samuel Oschin Comprehensive Cancer Institute, The Angeles Clinic and Research Institute, Tower Hematology Oncology Medical Group, Torrance Memorial Hunt Cancer Center and Cedars-Sinai Tarzana.

Latest from Cedars-Sinai Cancer

Dr. Figlin on Sunitinib for Patients With RCC

November 09, 2015

Video

Robert Figlin, MD, FACP, professor of Medicine and Biomedical Sciences, Steven Spielberg Family Chair in Hematology Oncology, director, Division of Hematology Oncology, deputy director, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, discusses newer methods of administering sunitinib (Sutent) to patients with renal cell carcinoma.

Ten Years After Sorafenib, TKIs Are Still Advancing Kidney Cancer Treatment

October 13, 2015

Article

Robert Figlin, MD, discusses the evolution of TKIs in renal cell carcinoma, the novel agents and changes to established therapies he is most excited about, and the challenges that still remain.

PEGPH20 Shows Promise in HA-High Pancreatic Cancer

August 07, 2015

Article

Andrew Hendifar, MD, discusses how PEGPH20 improved progression-free survival by 4.9 months in patients with advanced pancreatic cancer with high expression levels of hyaluronan.

Dr. Figlin on Ongoing ADAPT Trial for mRCC

July 14, 2015

Video

Robert Figlin, MD, FACP, professor of Medicine and Biomedical Sciences, Steven Spielberg Family Chair in Hematology Oncology, director, Division of Hematology Oncology, deputy director, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai, discusses the ongoing phase III ADAPT trial, which examines AGS-003 combined with sunitinib for the treatment of patients with mRCC.

Antiangiogenesis Agents in Ovarian Cancer

March 29, 2015

Article

BJ Rimel, MD, discuss the current literature surrounding antiangiogenesis agents in ovarian cancer.

Dr. Posadas Discusses Cabozantinib in Prostate Cancer

June 11, 2014

Video

Edwin M. Posadas, MD, FACP, medical director, Urologic Oncology Program, Cedars-Sinai's Samuel Oschin Comprehensive Cancer Institute, discusses a translational phase II study of cabozantinib in men with metastatic castration-resistant prostate cancer(mCRPC) with visceral metastases with characterization of circulating tumor cells and large oncosomes.

New MRD Assay Helps Move Testing Forward in Multiple Myeloma Research

April 18, 2014

Article

An improved assay for assessing MRD status in patients with multiple myeloma is contributing to the momentum for using MRD as a surrogate endpoint for survival in clinical trials and as a tool with the potential to help guide therapy choices.

Dr. Durie on a More Sensitive Automated Flow Cytometry MRD Test

December 16, 2013

Video

Brian G.M. Durie, MD, chairman, International Myeloma Foundation, hematologist/oncologist, Cedars-Sinai Medical Center, Los Angeles, California, discusses a more sensitive automated flow cytometry minimal residual disease (MRD) test.